Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer

Kalbasi, 2015, Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer, JAMA Oncol, 1, 897, 10.1001/jamaoncol.2015.2316 Peeters, 2006, Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy, J Clin Oncol, 24, 1990, 10.1200/JCO.2005.05.2530 Heemsbergen, 2006, Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage, Int J Radiat Oncol Biol Phys, 66, 3, 10.1016/j.ijrobp.2006.03.055 Zelefsky, 2002, High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients, Int J Radiat Oncol Biol Phys, 53, 1111, 10.1016/S0360-3016(02)02857-2 De Meerleer, 2007, Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control, Radiother Oncol, 82, 160, 10.1016/j.radonc.2006.12.007 Lips, 2008, High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients, Radiat Oncol, 3, 10.1186/1748-717X-3-15 Dehnad, 2003, Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation, Radiother Oncol, 67, 295, 10.1016/S0167-8140(03)00078-1 Smeenk, 2012, An endorectal balloon reduces intrafraction prostate motion during radiotherapy, Int J Radiat Oncol Biol Phys, 83, 661, 10.1016/j.ijrobp.2011.07.028 Wortel, 2017, Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels, Int J Radiat Oncol Biol Phys, 99, 1243, 10.1016/j.ijrobp.2017.07.044 Brenner, 1999, Fractionation and protraction for radiotherapy of prostate carcinoma, Int J Radiat Oncol Biol Phys, 43, 1095, 10.1016/S0360-3016(98)00438-6 Dasu, 2007, Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?, Clin Oncol (R Coll Radiol), 19, 289, 10.1016/j.clon.2007.02.007 Miralbell R, Roberts SA, Zubizarreta E, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):e17-2410.1016/j.ijrobp.2010.10.075. Coote, 2009, Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity, Int J Radiat Oncol Biol Phys, 74, 1121, 10.1016/j.ijrobp.2008.09.032 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4 Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 17, 1061, 10.1016/S1470-2045(16)30070-5 Morgan, 2018, Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline, J Urol, 10.1016/j.juro.2018.10.001 Kupelian, 2005, Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes, Int J Radiat Oncol Biol Phys, 63, 1463, 10.1016/j.ijrobp.2005.05.054 Skala, 2007, Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer, Int J Radiat Oncol Biol Phys, 68, 690, 10.1016/j.ijrobp.2006.12.064 Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618-2910.1016/j.eururo.2016.08.003 [published Online First: 2016/08/30]. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58(6):843-8. [published Online First: 2001/12/18]. Wei, 2000, Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer, Urology, 56, 899, 10.1016/S0090-4295(00)00858-X Cremers, 2010, Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy, Radiother Oncol, 97, 467, 10.1016/j.radonc.2010.05.023 Peeters, 2005, Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy, Int J Radiat Oncol Biol Phys, 61, 1019, 10.1016/j.ijrobp.2004.07.715 Roach, 2006, Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials, J Urol, 176, 10.1016/j.juro.2006.06.081 Pollack, 2013, Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, 31, 3860, 10.1200/JCO.2013.51.1972 Bryant, 2016, Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer, Int J Radiat Oncol Biol Phys, 95, 422, 10.1016/j.ijrobp.2016.02.038 Shaikh, 2017, Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer, Int J Radiat Oncol Biol Phys, 97, 722, 10.1016/j.ijrobp.2016.12.034 Schmid, 2012, Late gastrointestinal and urogenital side-effects after radiotherapy–incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer, Radiother Oncol, 104, 114, 10.1016/j.radonc.2012.05.007 Aluwini, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial, Lancet Oncol, 17, 464, 10.1016/S1470-2045(15)00567-7 Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol 2012;19(4):6373-80.